Connect with us

Technology

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Published

on

STOCKHOLM, Feb. 29, 2024 /PRNewswire/ — BioArctic AB (publ) (STO: BIOA-B) today announced that the company and its partner Eisai will present new data on lecanemab (brand name: Leqembi®) at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™), to be held in Lisbon, Portugal and virtually, March 5-9. In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic’s founder Professor Lars Lannfelt.

Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai, and the anti-amyloid beta (Aβ) protofibril antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer’s disease.

At AD/PD, BioArctic will present one oral presentation and one poster on lecanemab, both focused on the binding properties of lecanemab to various types of Aβ of lecanemab compared to several other Aβ antibodies. The company will also have two other posters related to Alzheimer’s disease.

In addition to BioArctic’s presentations, Eisai will present four oral presentations on lecanemab results. From the Phase 3 Clarity AD study in early Alzheimer’s disease[1] with confirmed brain Aβ accumulation, data will include the effect of lecanemab treatment on tau[2] accumulation in whole brain regions, and outcomes of long-term efficacy of lecanemab. In addition, the differences in the binding properties of multiple anti-amyloid (Aβ) antibodies to various types of Aβ and other data will be presented.

Eisai will also sponsor a symposium featuring three prominent clinical experts in the field of Alzheimer’s disease, Dr. Jeffrey Cummings, Dr. Robert Perneczky and Dr. Miia Kivipelto. Dr. Jeffrey Cummings will chair the symposium, and provide an overview of meaningful benefits, including clinical meaningfulness and the evolution of approaches for the clinical study of Alzheimer’s disease. Dr. Robert Perneczky will discuss how to assess meaningful benefits of treatments in development for Alzheimer’s disease. Dr. Miia Kivipelto’s presentation will provide new statistical methods to measure meaningful benefits and address various stakeholder perspectives.

Furthermore, Eisai’s Chief Clinical Officer, Lynn Kramer, M.D., will give a plenary presentation titled “Novel approaches to clinical development and the future potential of simulated placebo” on March 7 at the “Aβ TARGETING THERAPIES IN AD 1” session.

Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for a joint commercialization in the region.

Presentations by BioArctic and Eisai

Oral presentations

Asset in Development, Session, Time

Presentation Title

Lecanemab
Abeta Targeting Therapies in AD 01
Thursday, March 7, 13:50 – 14:05

Treatment with lecanemab disrupts tau accumulation across brain regions in early Alzheimer’s disease

Lecanemab
Abeta Targeting Therapies in AD 02

Saturday, March 9, 8:40 – 8:55

Binding characteristics of lecanemab, donanemab and other amyloid-beta antibodies to different forms of amyloid-beta in Alzheimer’s disease brains
                                   
Presented by BioArctic

Lecanemab
Abeta Targeting Therapies in AD 02
Saturday, March 9, 9:10 – 9:25

Lecanemab for the treatment of early Alzheimer’s disease: the extension of efficacy results from Clarity AD

Lecanemab
Abeta Targeting Therapies in AD 02
Saturday, March 9, 9:25-9:40

Structural dynamics of amyloid-β protofibrils and action of lecanemab as observed by high-speed atomic force microscopy 

Lecanemab
Virtual Oral Presentation
 VO028 / #2922

A neuro-dynamic quantitative systems pharmacology (QSP) model for Alzheimer’s disease incorporating amyloid and tau pathophysiology

Poster presentations

Asset in Development, Topic, Poster Number

Presentation Title

Lecanemab
P0213 / #1510

March 8 to 9

Characterization of amyloid-beta species in Alzheimer’s disease brain and the unique binding properties of lecanemab
                                   
Presented by BioArctic

General AD
P0110 / #562

March 8 to 9

Increased level of 12 KDA C-terminal ApoE fragments in AD brainPresented by BioArctic

General AD
P0111 / #943

March 8 to 9

Functional and morphological effects of 12 KDA C-terminal ApoE fragments in rat cortex culturesPresented by BioArctic

Eisai-Sponsored Symposium

Time

Title, Presenter

Thursday, March 7, 11:10 – 12:50

Defining meaningful benefits to patients, caregivers, and healthcare systems in Alzheimer’s diseaseJeffrey Cummings, Robert Perneczky, Miia Kivipelto,

Plenary presentation

Session, Time

Title

Abeta Targeting Therapies in AD 01
Thursday, March 7, 15:20 – 15:35

Novel approaches to clinical development and the future potential of simulated placebo

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.

The information was released for public disclosure, through the agency of the contact persons below, on February 29, 2024, at 08.00 a.m. CET

For further information, please contact: 

Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80 

Jiang Millington, Director Corporate Communication and Social Media
E-mail: jiang.millington@bioarctic.se
Phone: +46 79 33 99 166

About lecanemab (generic name, U.S., Japan and China brand name: Leqembi®)

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). In the U.S., Leqembi was granted traditional approval by the US Food and Drug Administration (FDA) on July 6, 2023. Leqembi is indicated as a disease-modifying treatment for Alzheimer’s disease (AD) in the US. Treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Please see full U.S. Prescribing Information.

In Japan, Eisai received approval from the Ministry of Health, Labour and Welfare (MHLW) on September 25, 2023, to manufacture and market lecanemab as a treatment for slowing progression of MCI and mild dementia due to AD. Furthermore, in China, Leqembi was approved by the National Medical Products Administration (NMPA) as a treatment of MCI due to AD and mild AD dementia in January 2024.

Eisai has also submitted applications for approval of lecanemab in 14 different countries, including EU, Canada and Great Britain.

Eisai has completed a lecanemab subcutaneous bioavailability study, and subcutaneous dosing is currently being evaluated in the Clarity AD (Study 301) open-label extension (OLE) study. A maintenance dosing regimen has been evaluated as part of the Phase 2b study (Study 201).

Since July 2020 Eisai’s Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health and Eisai.

Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

About the collaboration between BioArctic and Eisai

Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease. Several of the projects utilize the company’s proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic’s B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se.

[1] Early Alzheimer’s disease includes mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease

[2] A protein that aggregates intracellularly in nerve cells in Alzheimer’s disease, disrupting both the function and survival of the cell. Tau levels can be measured in plasma, cerebrospinal fluid, and with a positron camera (PET).

The following files are available for download:

https://mb.cision.com/Main/9978/3937731/2636450.pdf

Latest data on lecanemab to be presented at the 2024 AD/PDâ„¢ congress

 

View original content:https://www.prnewswire.co.uk/news-releases/bioarctic-latest-data-on-lecanemab-to-be-presented-at-the-2024-adpd-congress-302075416.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Protiviti Congratulates Brand Ambassador Matt Fitzpatrick as Fitzpatrick Brothers Win Zurich Classic of New Orleans

Published

on

By

Alex Fitzpatrick Earns PGA TOUR Card

MENLO PARK, Calif., April 26, 2026 /PRNewswire/ — Protiviti Golf Brand Ambassador and professional golfer Matt Fitzpatrick continued his strong 2026 season with a victory at the Zurich Classic of New Orleans alongside his brother, Alex Fitzpatrick. The Fitzpatrick brothers delivered a composed and cohesive performance throughout the team-format event, completing rounds of 64-65-57-71 (-31). The win secured Alex Fitzpatrick his first PGA TOUR card, marking a significant milestone in his professional career.

This marks Matt Fitzpatrick’s third win of the season, most on the PGA Tour, the 14th professional win of his career, and fifth on the PGA Tour. Fitzpatrick is currently No.1 on the FedEx Cup ranking and No. 3 in the Official World Golf Ranking, the highest ranking of his career. 

To commemorate Fitzpatrick’s win, Protiviti donated 25,000 meals through its “Birdies for Meals” campaign. Since its launch in 2021, the Birdies for Meals program has already donated more than 825,000 meals to people in need. 

“Congratulations to Matt Fitzpatrick and Alex Fitzpatrick on an outstanding victory—an inspiring showcase of chemistry and consistency. We also applaud Alex on earning his PGA TOUR card, a significant step in his career,” said Joseph Tarantino, Protiviti’s president and CEO. “In celebration of this win, Protiviti will donate 25,000 meals through our Birdies for Meals campaign, extending the impact well beyond the course.”

As Matt Fitzpatrick’s Official Performance Data Partner, Protiviti collaborates closely with Matt and his coaching team to enhance performance through advanced analytics and technology. By leveraging Microsoft technologies, Protiviti has developed a custom analytics platform, tailored dashboards, and a mobile application that streamline data collection and deliver real-time, shot-level insights. These tools enable more informed, data-driven decision-making across practice and competition, helping identify trends, refine preparation, and improve consistency. Learn more at www.protiviti.com/golf-data.

“It has been an incredible opportunity to work with Matt and see Protiviti’s work play a role in his on-course success. Just as we do with many clients, our team has built a bespoke program leveraging emerging technologies, advanced analytics and artificial intelligence to provide Matt, his caddie, and coaches with analysis and insights that aid in his preparation and guide strategy for each event he plays,” said Nick Ciafardini, associate director, Innovation for Protiviti.

“This win is surreal for me, especially doing it alongside my brother. I’m incredibly proud of Alex earning his PGA TOUR card—it’s a huge milestone for him and one we’ll always share. I’m also so grateful for the unwavering support from my family, my team, and my partners at Protiviti, whose data-driven approach to performance has become a key part of my preparation and constant pursuit of improvement,” said Matt Fitzpatrick.

After taking control with a historic 15-under in the fourball third round, the Fitzpatrick brothers briefly dropped the lead in the final round. With the tournament on the line at the 18th, they delivered a clutch closing sequence to seal the victory. Matt’s precision tee-to-green and Alex’s timely putting proved decisive, highlighting their chemistry under pressure.

Other notable Fitzpatrick wins include the 2015 British Masters, 2016 Nordea Masters, the 2016, 2020, and 2025 DP World Tour Championships. On the PGA Tour, Fitzpatrick also won the 2022 U.S. Open, RBC Heritage (2023 & 2026) and the 2026 Valspar Championship. He has been a Protiviti brand ambassador since 2020.

For more information about Protiviti’s golf brand ambassador program, please visit www.protiviti.com/golf.

About Protiviti 
Protiviti (www.protiviti.com) is a global consulting firm that helps clients transform and protect their businesses, and respond to planned and unexpected events. Through a network of more than 90 offices in over 25 countries, Protiviti and its independent and locally owned member firms deliver deep expertise and tailored capabilities across technology, artificial intelligence, data, operations, finance, legal, compliance, HR, marketing, digital, risk, and internal audit – enabling organizations to accelerate innovation, navigate risks and safeguard what matters most.

Named to the Fortune 100 Best Companies to Work For® list since 2015, Protiviti Inc. has served more than 80 percent of Fortune 100 and nearly 80 percent of Fortune 500 companies. The firm also works with government agencies and smaller, growing companies, including those looking to go public. Protiviti Inc. is a wholly owned subsidiary of Robert Half (NYSE: RHI).

View original content to download multimedia:https://www.prnewswire.com/news-releases/protiviti-congratulates-brand-ambassador-matt-fitzpatrick-as-fitzpatrick-brothers-win-zurich-classic-of-new-orleans-302753847.html

SOURCE Protiviti

Continue Reading

Technology

Plug and Play partners with the Nigerian Institution of Marine Engineers and Naval Architects to elevate Nigeria’s maritime ecosystem

Published

on

By

SINGAPORE, April 27, 2026 /PRNewswire/ — Plug and Play, the world’s largest open innovation platform headquartered in Silicon Valley, announced a strategic partnership with the Nigerian Institution of Marine Engineers and Naval Architects (NIMENA) to accelerate the transformation of Nigeria’s maritime sector into a globally competitive innovation hub.

The partnership will connect Nigeria’s maritime ecosystem to global standards, networks, and capital by leveraging Plug and Play’s international corporate partnerships, accelerator expertise, and cross-border innovation infrastructure.

At its core, the collaboration will launch a dedicated maritime & energy innovation platform focused on advancing engineering-led technologies across maritime, energy, supply chain, and logistics sectors. The initiative will involve the development of a startup pipeline between Nigeria and Singapore, widely regarded as one of the world’s most advanced maritime & energy innovation ecosystems serving as a neutral and trusted testbed for technology validation. 

Through this program, selected startups will receive:

Access to cutting-edge technologies and global industry insightsStructured mentorship from international maritime & energy innovation leadersPilot and proof-of-concept opportunities in a globally benchmarked ecosystemCommercialization pathways into the Nigerian marketBusiness development and investor-readiness supportOpportunities for cross-border partnerships and market expansion

By ensuring that solutions being scaled into Nigeria have been validated in overseas markets the program minimizes adoption risks while accelerating technology transfer and investment flows into the Nigerian maritime & energy sector.

“Engineering-driven innovation is critical to solving some of the world’s most complex challenges—from sustainable shipping to the decarbonization of marine operations,” said Jupe Tan, Managing Partner, APAC, Plug and Play. “By partnering with NIMENA, we are creating a trusted bridge between global innovation ecosystems and Nigeria’s maritime & energy sector, unlocking pathways for international collaboration and long-term competitiveness.”

“This partnership marks a transformative step for Nigeria’s energy and maritime innovation ecosystem,” said Dr. Eferebo Sylvanus, National Chairman, NIMENA. “By aligning with global standards and connecting our local talent to international platforms, we are creating new opportunities for Nigerian innovators to scale their solutions beyond borders while strengthening our national capabilities.”

Addressing Critical Ecosystem Gaps

1. Strengthening Ecosystem Alignment

To address fragmentation across government, academia, and industry stakeholders, Plug and Play has conducted a comprehensive ecosystem assessment. This data-driven evaluation examines capital access, talent pipelines, infrastructure readiness, and regulatory frameworks—culminating in a Strategic Ambition and Vertical Map for Nigeria’s maritime sector.

2. Creating a Stronger Investment Pipeline

While sector-specific funding opportunities exist, structured validation and vetting mechanisms remain limited. Under this partnership, Plug and Play will curate high-potential stage agnostic startups directing capital toward scalable, innovation-driven ventures with strong technical and commercial viability.

3. Enabling Global Market Access

The partnership will provide stage-agnostic startups with exposure to large corporations, regulators, and investors. Successful technologies will transition into exploring scaling opportunities in Nigeria for commercialization, positioning Nigeria as a high-growth destination for innovation across Africa.

A Bridge Between Global Trust and Local Scale

More than an accelerator program, the Plug and Play–NIMENA partnership is designed as a long-term platform for trust-building, knowledge transfer, and ecosystem anchoring.

Singapore will serve as the gateway for technology validation and international credibility, while Nigeria will serve as the destination for scaling, commercialization, and impact. This dual-ecosystem model ensures that cutting-edge solutions are introduced with global benchmarks while enabling sustainable, locally anchored growth.

As international startups expand into Nigeria, they will establish local operations, drive knowledge transfer, build intellectual property, and create high-value employment opportunities. Over time, this approach will not only attract foreign innovators but also catalyze the rise of homegrown Nigerian startups capable of contributing solutions to the global maritime industry.

By combining NIMENA’s technical leadership with Plug and Play’s global innovation infrastructure, the partnership represents a decisive step toward positioning Nigeria as an innovation hub for Africa, and a leader for maritime, energy, and adjacent industries for the region, ultimately strengthening competitiveness, accelerating entrepreneurship and advancement of technologies in their market, and aligning the national ecosystem with global best practices.

For partnership and participation inquiries:

Industry stakeholders interested in partnering are invited to connect with the team. We are actively seeking corporate and institutional partners to collaborate on pilot projects, proof-of-concept initiatives, and ecosystem development efforts. Global startups developing solutions across maritime, energy, logistics, supply chain, and related sectors are also encouraged to reach out to be considered for participation in the program.

For more information, please contact  nimena-program@pnptc.com

About the partners:

About Plug and Play

Plug and Play is the leading global innovation platform connecting startups, corporations, venture capital firms, universities, and government agencies. Headquartered in Silicon Valley, Plug and Play operates in more than 60 locations across five continents, helping corporate partners and founders in every stage of the innovation journey — from education to execution. Plug and Play runs startup acceleration programs, corporate innovation services, and an in-house venture capital platform that has invested in hundreds of successful companies, including Dropbox, PayPal, Honey, LendingClub, N26, and Rappi. For more information, visit https://www.plugandplayapac.com/

About the Nigerian Institution of Marine Engineers and Naval Architects (NIMENA)

The Nigerian Institution of Marine Engineers and Naval Architects (NIMENA) is a professional body consisting of Naval Architects, Marine Engineers, and allied professions. NIMENA is dedicated to strengthening professional standards, fostering technological innovation, promoting capacity, and sustainable development in Nigeria’s maritime sector. The institution provides thought leadership, professional development opportunities, technical workshops, and industry events to support maritime engineering excellence and capacity building. For more information, visit https://nimena.org.ng/home.html

View original content:https://www.prnewswire.com/apac/news-releases/plug-and-play-partners-with-the-nigerian-institution-of-marine-engineers-and-naval-architects-to-elevate-nigerias-maritime-ecosystem-302753673.html

SOURCE Plug and Play

Continue Reading

Technology

TPIsoftware Wins “Taiwan SMART 50 Award” for Its FHIR-Based Medical AI Application

Published

on

By

TAIPEI, April 26, 2026 /PRNewswire/ — TPIsoftware (TPEx: 7781) was honored with the first Taiwan SMART 50 Award for creating a FHIR-based Medical AI Application.

Organized by the Ministry of Health and Welfare, the award encourages the development of smart health apps that align with the SMART on FHIR standard to enable secure and real-time data sharing across different hospitals. 50 apps were selected from 115 submissions through an open call. These apps will be listed on the Taiwan Health App Space (THAS) as part of the country’s initiative to foster data interoperability in healthcare.

TPIsoftware’s submission of an AI-powered procedural coding tool, which is a module of its healthcare solution digiCare, has been proven to be practically effective and compliant with SMART on FHIR.

The procedural coding app uses Natural Language Processing (NLP) to identify whether a contrast agent is applied or specify anatomical sites in a radiology report. The tool generates suggested codes once clinical details are recognized, which medical professionals can then review and manually revise. The automated workflow improves coding accuracy, reduces denied claims and ensures compliance with ICD-10-PCS and DICOM. The data entry process is streamlined since the tool is compatible with existing systems such as EHR and HIS, freeing up staff to handle complex patient concerns and care journeys.

“Being named one of the SMART 50 Apps demonstrates our R&D capacity in supporting healthcare transformation. The standardized framework enables hospitals and medical centers to provide informed, high-quality care with greater consistency, security and plug-and-play simplicity,” said Pierre Hsia, Executive Vice President of Enterprise Application Development Division at TPIsoftware.

TPIsoftware General Manager Yilan Yeh attributed the accolade to the company’s domain expertise and years of experience in highly-regulated industries. “Partnerships among industry leaders, academic institutions, healthcare providers and government agencies are nurtured to support patient-centered care, clinical decisions and treatment. Following the model of the US All of Us Research Program, we are committed to building Taiwan’s national database aligned with the TW Core Implementation Guide (IG) and FHIR standard, where data are made accessible within an open, standardized ecosystem.”

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/tpisoftware-wins-taiwan-smart-50-award-for-its-fhir-based-medical-ai-application-302751606.html

SOURCE TPIsoftware

Continue Reading

Trending